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OBJECTIVE — Thehypothesisofcarotenoidhavingapreventiveroleindiabetesissuggested
by their antioxidant properties. In this report, we investigated the relationship between baseline
total plasma carotenoid levels and 9-year onset of dysglycemia (impaired fasting glucose or type
2 diabetes) in a healthy elderly population.
RESEARCH DESIGN AND METHODS — The Epidemiology of Vascular Ageing Study
is a 9-year longitudinal study including 1,389 volunteers aged 59–71 years. Fasting plasma
glucose was measured at baseline and at 2, 4, and 9 years after inclusion. The relationship
between plasma carotenoid at baseline and incidence of dysglycemia was determined by Cox
proportional hazards regression analysis adjusting for potential confounders.
RESULTS — At 9 years, 127 incident cases of dysglycemia had occurred. Risk of dysglycemia
was signiﬁcantly lower in participants with plasma carotenoid in the highest quartile (Q4)
compared with participants in the lowest quartile (Q1) (Q4 vs. Q1: relative risk 0.26 [95% CI
0.14–0.49], P  10
4; Q3 vs. Q1: 0.55 [0.34–0.89], P  0.01; and Q2 vs. Q1: 0.82 [0.51–
1.31], P  0.40). After controlling for sociodemographic variables, lifestyle habits, cardiovas-
cular disease, blood pressure, BMI, and lipid proﬁle, risk of dysglycemia remained signiﬁcantly
lower in participants in the highest quartile of total plasma carotenoid compared with partici-
pants in the lowest quartile (Q4 vs. Q1: 0.42 [0.22–0.82], P  0.01; Q3 vs. Q1: 0.69 [0.41–
1.15], P  0.16; and Q2 vs. Q1: 0.80 [0.48–1.32], P  0.38).
CONCLUSIONS — Thisstudyprospectivelyconﬁrmsthatplasmacarotenoidlevelshavean
independent relationship to onset of dysglycemia.
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arotenoids are natural pigments
synthesized by plants and microor-
ganisms but not by animals or by
humans. These pigments are found in
food, especially in fruits and vegetables.
It is highly suggested that they play a
protectiveroleinchronicdiseases(1)or
cancers. Even if the biological mecha-
nisms for such a protection are cur-
rently unclear (2), their protective
effects could come from their antioxi-
dant properties (3).
Several cross-sectional (4–6) and
case-control (7–9) studies have shown an
inverse relationship between serum car-
otenes and type 2 diabetes status. A lon-
gitudinal study (10) on dietary intake of
antioxidants found a signiﬁcant relation-
ship between -cryptoxanthin intake and
reduced risk of type 2 diabetes; however,
theassociationbetweenserumcarotenoid
and diabetes was called into question by
the results of two other longitudinal stud-
ies (11,12) and one randomized double-
blind trial (13).
To investigate if carotenoids could
have a role in diabetes incidence in the el-
derly, possibly through their antioxidant
capacity, we explored the relationships
between total plasma carotenoid levels at
baseline and 9-year occurrence of type 2
diabetesorimpairedfastingglucose(IFG)
in a healthy elderly population.
RESEARCH DESIGN AND
METHODS— The Epidemiology of
Vascular Ageing (EVA) study is a 9-year
longitudinal study with six waves of fol-
low-up (14). At baseline (EVA0, 1991–
1993), 1,389 volunteers (574 men and
815 women) born between 1922 and
1932 (mean age of 65 years) residing in
thetownofNantes(westernFrance)were
recruited from electoral rolls and, to a
lesser extent, via information campaigns.
The subsequent follow-up waves with bi-
ological measurements were EVA2 (2-
yearfollow-up,n1,272),EVA3(4-year
follow-up, n  1,188), and EVA6 (9-year
follow-up, n  781). The study protocol
was approved by the ethical committee of
the University Center Hospital of Krem-
lin-Bice ˆtre, Paris, France. Signed in-
formed consent was obtained from all
participants at enrollment. For the pur-
pose of the present article, analyses were
carried out on 1,165 participants who
were normoglycemic at inclusion, de-
ﬁned by a fasting blood glucose (FBG)
6.1 mmol/l and not being on antidiabe-
tes drugs, and for whom plasma carot-
enoid measurement was available.
Blood samples were drawn between
8:30 and 9:30 A.M. after a 12-h fast. Bio-
logical procedures for the determination
ofglucoselevelshavebeendescribedelse-
where (15). According to the World
Health Organization deﬁnition (16), par-
ticipants with an FBG 7.00 mmol/l or
whousedantidiabetesdrugsweredeﬁned
as having diabetes. Participants with IFG
were characterized by 6.1  FBG  7
mmol/l (16). Dysglycemia was deﬁned by
presenceofIFGordiabetesstatus.During
the 9-year follow-up, cumulative inci-
dence of dysglycemia was considered. To
account for the reversibility of IFG, we
deﬁned persistent IFG as having dysgly-
cemia at least two times on the three fol-
low-up waves.
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allowed us to obtain information on so-
ciodemographic factors (sex, age, and ed-
ucation) and lifestyle habits (smoking
habits and alcohol intake). In addition,
height and weight were measured. Two
independent measures of systolic and di-
astolic blood pressure were taken with a
digital electronic tensiometer after a 10-
min rest. Health characteristics consid-
ered in these analyses were BMI, total-to-
HDL cholesterol ratio, use of lipid-
lowering drugs, hypertension (systolic or
diastolic blood pressure 140 or 90
mmHg, respectively, or use of hyperten-
sive drugs), and history of vascular dis-
eases (self-reported history of myocardial
infarction, angina pectoris, or stroke).
Total plasma carotenoid levels were
determined only at baseline by using a
spectrophotometric assay. Samples were
immediately frozen at 20°C then stored
at 80°C, and all the determinations
were done at the same time (2 years after
the ﬁrst inclusion). After precipitation of
plasma proteins with ethanol, carote-
noids were extracted with hexane and
measurements of absorbance on the hex-
ane phase at 350, 450, and 550 nm were
performed (spectrophotometer Uvikon
860; Kontron, Rotkreuz, Switzerland).
Concentrations were calculated on the
basis of a molecular extinction factor at
450 nm of 134,000 l   mol
1   cm
1.A b -
sorbance values at 350 and 550 nm were
usedtocorrecttheabsorbanceobtainedat
450 nm by applying an adequate equa-
tion. Coefﬁcients of intra- and interassay
variationwere5.4and4.9%,respectively.
Statistical methods
Sex, education (primary school or lower/
high school or higher), smoking status
(current,ex-smokers,ornonsmokers),al-
cohol intake (20 ml/20 ml per day),
cardiovascular disease antecedents (yes/
no), and use of lipid-lowering drugs (yes/
no) were considered as categorical
variables. Age, BMI, diastolic and systolic
blood pressure, and the total-to-HDL
cholesterol ratio were considered as con-
tinuous variables. The total plasma carot-
enoid level was considered by quartile.
The median and range values for each
quartilewere1.42mol/l(0.21–1.82)for
Q1 (25th), 2.16 mol/l (1.83–2.53) for
Q2 (25th, 50th), 2.90 mol/l (2.55–
3.43) for Q3 (50th, 75th), and 4.14
mol/l (3.44–10.1) for Q4 (75th). By
using the Student’s t test (for continuous
variables) and the 
2 test (for categorical
variables), baseline characteristics were
compared between participants who de-
veloped dysglycemia during the fol-
low-up and those who did not and
between participants who completed the
9-year follow-up and those who did not.
Survival analyses by actuarial methods
were used to assess the probability of not
developing dysglycemia according to lev-
els of plasma carotenoids. The effects of
total plasma carotenoid levels on onset of
dysglycemia were determined by Cox
proportional hazards regression models,
in which age (in years) during the study
was used as the time axis, with left trun-
cation at age of study entry. To take into
account the reversibility of IFG, addi-
tionalsensitivityanalyseswereperformed
after considering persistent IFG. To ex-
plore whether relationships with carote-
noids could be confounded by their
antioxidant capacity, similar analyses
wereperformedonparticipants(n875)
for whom different markers of antioxi-
dant status, such as thiobarbiturate reac-
tive substances, vitamin E, activity of
glutathioneperoxydases,andsuperoxyde
dismutase, were measured as baseline
(methoddescribedinBerretal.[15]).The
proportional hazards assumption was
veriﬁed by adding a time-dependent vari-
able to the model. Results of Cox multi-
variate regressions were expressed by
hazardratio(95%CI).Allinteractionsbe-
tween total plasma carotenoids and other
variables were tested. Statistical analyses
were performed using SAS software ver-
sion 9.1 (SAS Institute, Cary, NC).
RESULTS— Duringthe9-yearfollow-
up, 127 new cases of dysglycemia (in-
cluding 29 cases of type 2 diabetes)
occurred.Sixty-fourcases(includingnine
cases of diabetes) occurred during the
ﬁrst 2 years of follow-up (EVA2, base-
line). Forty cases (including 10 cases of
diabetes) occurred between EVA2 and
EVA3, and 23 cases (including 10 of dia-
betes) occurred between EVA3 and
EVA6. Characteristics of the 635 partici-
pants who completed the 9-year fol-
low-up were compared with the 530 who
did not (including 101 deaths). Partici-
pants who did not complete the whole
study were more likely to be current or
former smokers (43.4 vs. 37.5%, P 
0.04), to have higher baseline diastolic
blood pressure (79.5  11.0 vs. 78. 2 
10.7 mmHg, P  0.03), and have lower
baseline total plasma carotenoid levels
(2.711.23vs.2.911.32mol/l,P
0.008).
Among the 127 participants who de-
veloped a dysglycemia during the 9-year
follow-up,theproportionofmen,current
Table 1—Comparison of baseline characteristics between participants who developed dysg-
lycemia during the 9-year follow-up and those who did not: results of bivariate analyses
Participants
P value
Did not develop
dysglycemia
Developed
dysglycemia
n 1,038 127
Sociodemographic factors
Women 63.9 44.7 10
4
Age at baseline (years) 65.0  3.0 64.9  3.1 0.72
Higher education* 48.5 47.1 0.78
Consumption factors
Current/former smokers 38.7 52.8 0.002
Alcohol consumer (20 ml/day)* 26.0 39.2 0.002
Health factors
BMI (kg/m
2)* 24.7  3.4 27.0  3.7 10
4
HDL cholesterol (mmol/l)* 1.69  0.43 1.50  0.42 10
4
Total cholesterol (mmol/l)* 6.43  1.01 6.30  0.98 0.17
Total-to-HDL cholesterol ratio* 4.03  1.15 4.49  1.45 0.01
Lipid-lowering drugs user 22.8 27.6 0.23
Systolic blood pressure (mmHg)* 130.0  17.6 136.4  16.0 0.0001
Diastolic blood pressure (mmHg)* 78.4  10.8 82.0  11.1 0.0006
Cardiovascular disease antecedents 8.6 8.9 0.91
Total plasma carotenoid (mol/l) 2.87  1.29 2.37  1.10 10
4
DataaremeansSDorpercent.*Analyseswereperformedon1,164participantsforeducationlevel,1,144
foralcoholconsumption,1,164forbloodpressure,1,162forBMI,1,121forLDLcholesterol,1,130forHDL
cholesterol, and 1,139 for total cholesterol.
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ers of alcohol was signiﬁcantly higher
compared with the 1,038 participants
who did not develop dysglycemia (Table
1). A signiﬁcantly higher BMI and dia-
stolic and systolic blood pressure and
lower HDL cholesterol concentration at
baseline were also observed in the dysg-
lycemic group. No signiﬁcant difference
wasobservedinbaselinetotalcholesterol,
proportion of lipid-lowering drug users,
cardiovascular diseases history, and age
between the two groups. Bivariate analy-
ses also showed that total baseline plasma
carotenoid levels were signiﬁcantly lower
in participants who developed dysglyce-
mia compared with those who did not
(Table 1).
Factors associated with total plasma
carotenoids at baseline are described in
Table 2. A higher proportion of women
were found in higher quartiles of total
plasmacarotenoids,andahigherpercent-
age of smokers and alcohol consumers
wereobservedinlowerquartiles.BMI,di-
astolic and systolic blood pressure, and
cardiovascular disease history decreased
with higher levels of plasma carotenoids.
Highlevelsofcarotenoidswereassociated
with an increase of total cholesterol and a
decrease of HDL cholesterol, and there
was a higher proportion of lipid-lowering
drug users in low quartiles of plasma ca-
rotenoid levels.
Comparisonsofsurvivaldistributions
between quartiles of plasma carotenoids
showed that the lower the quartile the
greater the occurrence of dysglycemia
(Fig. 1). The analysis showed that risk of
dysglycemia decreased signiﬁcantly in
participants with plasma carotenoids in
Q4andQ3comparedwithparticipantsin
Q1(Q4vs.Q1:relativerisk0.26[95%CI
0.14–0.49], P  10
–4; Q3 vs. Q1: 0.55
[0.34–0.89], P  0.01; and Q2 vs. Q1:
0.82 [0.51–1.31], P  0.40). Interactions
tested between plasma carotenoids and
different characteristics were not statisti-
cally signiﬁcant. Results of multivariate
Cox models (Table 3), after controlling
for sociodemographic factors, smoking
habits, alcohol intake, cardiovascular dis-
ease history, blood pressure, BMI, and
lipid proﬁle, showed that risk of dysgly-
cemia during the 9-year follow-up re-
mained signiﬁcantly lower in participants
in the highest quartile of total plasma
carotenoids compared with participants
in the lowest quartile (Q4 vs. Q1: 0.42
[0.22–0.82], P  0.01). The other ad-
justed risks did not remain signiﬁcant
(Q3 vs. Q1: 0.69 [0.41–1.15], P  0.16;
and Q2 vs. Q1: 0.80 [0.48–1.32], P 
0.38).Totakeintoaccountreversibilityof
Table 2—Factors associated with total plasma carotenoids at baseline
Plasma carotenoid quartiles
P trend
Quartile 1
(1.82 mol/l)
Quartile 2
(1.82–2.55 mol/l)
Quartile 3
(2.55–3.43 mol/l)
Quartile 4
(3.43 mol/l)
Sociodemographic factors
Women 40.1 52.5 65.8 83.2 10
4
Age at baseline (years) 64.7  2.9 65.3  2.8 65.0  3.1 64.8  3.0 0.06
Higher education 43.0 49.3 50.8 49.4 0.28
Consumption factors
Current/former smokers 56.2 48.2 37.9 22.5 10
4
Alcohol consumer (20 ml/day) 41.2 33.2 24.7 14.1 10
4
Health factors
BMI (kg/ m
2) 26.5  3.7 25.4  3.4 24.6  3.3 23.6  3.0 10
4
HDL cholesterol (mmol/l) 1.55  0.41 1.56  0.35 1.71  0.42 1.82  0.46 10
4
Total cholesterol (mmol/l) 5.98  0.99 6.23  0.91 6.47  0.91 6.86  1.01 10
4
Total-to-HDL cholesterol ratio 4.10  1.13 4.22  1.37 4.01  1.09 4.00  1.17 0.09
Lipid-lowering drugs user 32.5 26.9 20.4 15.9 10
4
Diastolic blood pressure (mmHg) 81.2  11.8 79.8  11.0 77.9  10.8 76.9  9.7 10
4
Systolic blood pressure (mmHg) 133.4  18.1 134.2  18.0 130.0  18.0 126.2  15.1 10
4
Cardiovascular disease
antecedents
13.2 11.7 4.70 6.3 0.0004
Data are means  SD or percent.
Figure 1—Nonoccurrence of dysglycemia for each total plasma carotenoid quartile group. Q1:
1.82 mol/l, Q2: 1.82–2.55 mol/l, Q3: 2.55–3.43 mol/l, Q4: 3.43 mol/l.  , Q1; u, Q2; Œ,
Q3; E, Q4.
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IFG as an end point were performed and
showed a similar graded association be-
tween quartiles of carotenoids and dysg-
lycemia (data not shown).
To test if the relationship was main-
tained after adjustment for antioxidant
markers,similaranalyseswereperformed
after adjustment for markers of antioxi-
dant status (thiobarbiturate reactive sub-
stances, vitamin E, activity of glutathione
peroxydase, and superoxyde dismutase).
Relative risks of dysglycemia associated
with quartile of total plasma carotenoid
levels were similar to those described in
Table 3 (Q4 vs. Q1: relative risk 0.38
[95% CI 0.19–0.79], P  0.009; Q3 vs.
Q1: 0.66 [0.40–1.15], P  0.15; and Q2
vs. Q1: 0.74 [0.43–1.27], P  0.28).
None of the markers of antioxidant stress
measured at baseline was signiﬁcantly as-
sociated with 9-year risk of dysglycemia.
CONCLUSIONS — Our results
showed that high levels of plasma carote-
noids at baseline were signiﬁcantly asso-
ciated with a lower 9-year risk of onset of
dysglycemia in a healthy elderly popula-
tion, independently of factors classically
associated with dysglycemia, such as so-
ciodemographic factors, lifestyle habits,
cardiovascular disease history, blood
pressure, BMI, and dyslipidemia. Fur-
thermore, the relation persisted after ad-
justmentformarkersofantioxidantstatus
(thiobarbiturate reactive substances, vita-
min E, activity of glutathione peroxydase,
and superoxyde dismutase). This suggests
thatplasmacarotenoidscouldbeinadirect
relation with dysglycemia. To our knowl-
edge, our study is one of the few that longi-
tudinally explore the relationship between
carotenoid and dysglycemia.
Many cross-sectional studies (4–9)
have shown this association. In a popula-
tion at high risk of type 2 diabetes, the
BotniaDietaryStudyshowedthathighdi-
etary intake of 	-carotene, -carotene,
andlycopeneandhighplasma-carotene
concentration were beneﬁcially associ-
ated with glucose metabolism in partici-
pants (6). The third National Health and
NutritionExaminationSurvey(5)andthe
Australian Diabetes, Obesity, and Life-
style Study (4) showed a signiﬁcant asso-
ciation between low serum -carotene
levels and type 2 diabetes. In a previous
publication (17), using baseline data of
the EVA study, we also reported a signif-
icant correlation between total plasma
carotenoids and glycemia. Finally, case-
control studies (8–9) also found lower
plasma carotenoid levels in diabetic pa-
tients than in control subjects, and one of
them (8) was carried out on an elderly
population. However, in this cross-
sectional framework, it is not possible to
know if low levels of carotenoids in dia-
betic participants are a consequence (the
results of increased utilization due to the
oxidative stress effects of the disease) or a
cause: are the low concentrations in-
volved in the pathogenesis of the disease?
Our longitudinal ﬁndings conﬁrm re-
sults from the prospective study led by
Montonen et al. (10) (23 years of follow-
up), which showed, in a cohort of 4,303
participants free of diabetes at baseline,
that -cryptoxanthin intake was signiﬁ-
cantly associated with a reduced risk of
type2diabetes(relativerisk0.58[95%CI
0.44–0.78]). Other longitudinal results
are more conﬂicting. In a nested case-
controlstudy(11)(106caseand201con-
trolsubjects,meanageof59.9years),risk
of diabetes was found to be lower in the
highest serum -carotene tertile group
compared with the lowest tertile; how-
ever, the signiﬁcant association did not
remain after adjustment for cardiovascu-
lar risk factors (0.94 [0.38–2.32]). More
recently, results of a nested case-control
study(470caseand470controlsubjects)
conductedonmiddle-agedandolderU.S.
women (aged 45 years) by Wang et al.
(12) did not conﬁrm the prospective as-
sociation between different baseline
plasma carotenoids compounds (lyco-
pene, 	-carotene, -carotene, -cryptox-
anthin,lutein,andzeaxanthin)andriskof
type 2 diabetes. The different methods
and the biovariability of carotenoids,
which is inﬂuenced by several factors
suchascharacteristicsofthefoodsources,
interactions with other dietary factors,
and various participant characteristics,
could explain the differences between
studies. Finally, a double-blind random-
ized controlled trial (13) of 12-year sup-
plementation of -carotene in a healthy
U.S. male cohort (n  22,071, aged
40–84 years) did not show a signiﬁcant
beneﬁt on risk of type 2 diabetes (396
incidentcasesinthesupplementedgroup
versus 402 cases in the placebo group;
relative risk 0.98 [0.85–1.12]). However,
results of this trial should be interpreted
with caution, as type 2 diabetes was not
the primary end point and diagnosis of
diabetes was self-reported without
screening for glucose tolerance.
Our study has limitations. The EVA
studyincludedvolunteerswithhighered-
ucational status and higher incomes than
the average elderly French population;
however, this should not have any effects
ontherelationshipbetweenplasmacarot-
enoidlevelsanddysglycemia.Forreasons
ofstatisticalpower(only29incidentcases
of diabetes), we considered IFG in the
dysglycemia deﬁnition. IFG is a risk situ-
ationfordiabetes;however,wecannotex-
clude that some participants have
reversed to normal. Thus, we cannot ex-
clude that we overdiagnosed dysglyce-
mia.However,ifthisisthecase,itislikely
to have weakened the true association be-
tween carotenoids and dysglycemia.
Table 3—Effects of total plasma carotenoids on onset of dysglycemia during the EVA study
follow-up: results of multivariate Cox proportional hazards regression analyses
Complete model
Multivariate models*
Hazard ratio
(95% CI) P
Total plasma carotenoids (mol/l)
Q4 vs. Q1 0.42 (0.22–0.82) 0.01†
Q3 vs. Q1 0.69 (0.41–1.15) 0.16†
Q2 vs. Q1 0.80 (0.48–1.32) 0.38†
Sex 0.90 (0.53–1.54) 0.71
Education (high versus low level) 0.91 (0.62–1.34) 0.63
Smoking habits (current/former versus nonsmoker) 1.08 (0.67–1.75) 0.74
Alcohol intake (20 vs. 20 ml) 1.18 (0.75–1.85) 0.47
Diastolic blood pressure (mmHg) 0.99 (0.96–1.01) 0.37
Systolic blood pressure (mmHg) 1.01 (0.99–1.03) 0.11
Cardiovascular disease antecedents (yes versus no) 0.69 (0.34–1.40) 0.30
Total-to-HDL cholesterol ratio 1.22 (1.06–1.40) 0.005
Lipid-lowering drugs user (yes versus no) 1.30 (0.85–1.98) 0.22
BMI (kg/m
2) 1.11 (1.05–1.17) 0.0002
*Adjustment for all variables listed in the table; model performed on 1,035 participants. †P trend  0.08.
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the persistent IFG deﬁnition showed that
the relation was maintained. Another
limitation comes from our carotenoid
measurement, insofar as only one mea-
surement was made using a spectropho-
tometry method, while the reversed-
phase high-performance liquid
chromatography method provides more
accurate measures with information on
different carotenoids. Unfortunately, in
1991, when the EVA study started, this
assay was not available for epidemiologi-
cal purposes. Furthermore, the blood
samples were equally collected through-
out the year in the EVA study. Finally,
another limitation is the high rate of attri-
tioninthiscohort.Participantslosttofol-
low-up had lower baseline total plasma
carotenoids. Most likely, this caused an
underestimation of the incidence of dys-
glycemia and consequently decreased the
power of the study. Despite these limita-
tions, the relationships we showed were
strong, almost in a dose-dependent fash-
ion, and remained signiﬁcant in the high-
est quartile after adjusting for various
potential confounders.
Currently, the mechanism of this po-
tential relationship is still under debate,
and, as it has been described by Paiva et
al.(2),severalhypothesescanexplainthis
observation.Oneoftheminvolvesantiox-
idant properties. In our study, analyses
wererepeatedaftercontrollingforvarious
antioxidative markers, and our results re-
mained unchanged, suggesting that the
association between total plasma carote-
noidsanddiabetesobservedinourcohort
is independent of the oxidative stress sta-
tusofsubjects.Otherhumanstudieshave
failed to show a clear beneﬁt of antioxi-
dants (18) and some studies have even
suggested that they can be potentially
harmful (18,19).
High plasma carotenoid is also a
marker of fruit and vegetable consumption
(20). A reduced risk of type 2 diabetes with
vegetable consumption was suggested in
severalstudies(21,22)butnotall(23).This
possible protective effect of fruit and vege-
table consumption in diabetes described in
these studies could result from the com-
bined action of many protective com-
pounds, including antioxidants, and could
explain the controversial literature results
between studies that were interested in
blood measurement levels of carotenoids
and those that were interested in carote-
noid-rich fruit and vegetable consumption.
Finally, we cannot exclude that carotenoids
might have been serving as markers for
other protective lifestyle habits and health
behaviors but are not acting as effective
agents themselves.
In conclusion, our results bring sup-
port to a possible role of carotenoids in
onsetofIFGandtype2diabetesinelderly
people. Further studies are necessary to
explorethemechanismthatcouldexplain
the relationship and hopefully design
original measures that could help prevent
dysglycemia.
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